Page 7 of 8
ACS Medicinal Chemistry Letters
3. Howard, S.J.; Catchpole, M.; Watson, J.; Davies, S.C. Antibiotic
(SQ109) pyrrole hybrid derivatives: discovery of potent anti-
tubercular agents effective against multi-drug resistant
mycobacteria. J. Med. Chem. 2016, 59, 2780–2793.
resistance: global response needed. Lancet Infect. Dis. 2013, 13,
1001 – 1003.
1
2
3
4
5
6
7
8
9
4. World
Health
Organization,
Tuberculosis.
18. Masci, D.; Hind, C.; Islam, M.K.; Toscani, A.; Clifford, M.; Coluccia,
A.; Conforti, I.; Touitou, M.; Memdouh, S.; Wei, X.; La Regina, G.;
Silvestri, R.; Sutton, J. M.; Castagnolo, D. Switching on the
activity of 1,5-diaryl-pyrrole derivatives against drug-resistant
ESKAPE bacteria: Structure-activity relationships and mode of
action studies. Eur J. Med. Chem. 2019, 178, 500-514
19. Manetti, F.; Magnani, M.; Castagnolo, D.; Passalacqua, L.; Botta,
M.; Corelli, F.; Saddi, M.; Deidda, D.; De Logu, A. “Ligand-Based
Virtual Screening, Parallel Solution-Phase and Microwave-
Assisted Synthesis as Tools to Identify and Synthesize New
Inhibitors of Mycobacterium Tuberculosis”, ChemMedChem
2006, 1, 973-989.
20. Manetti, F.; Corelli, F.; Biava, M.; Fioravanti, R.; Porretta, G. C.;
Botta, M. Building a pharmacophore model for a novel class of
antitubercular compounds. Il Farmaco, 2000, 55, 484–491
21. Biava, M.; Porretta, G.C.; Poce, G.; De Logu, A.; Saddi, M.;
Meleddu, R.; Manetti, F.; De Rossi, E.; Botta, M.1,5-
Diphenylpyrrole derivatives as antimycobacterial agents.
Probing the influence on antimycobacterial activity of
lipophilic substituents at the phenyl rings. J. Med. Chem. 2008,
51, 3644-3648.
22. The different activity observed is imputable to the different
strains and different methods used in London and Sao Paulo.
23. Details of the assay are reported in the Supporting Information.
The preliminary observations of toxicity in vivo will be
followed by further testing at higher doses and will be later
corroborated by in vivo experimentation in small mammals.
These studies are in progress and will published later.
24. de Steenwinkel, J. E. M.; de Knegt, G. J.; Kate, M. T.; Belkum, A.
Van; Verbrugh, H. A.; Kremer, K.; Van Soolingen, D.; Bakker-
Woudenberg, I. A. J. M. Time–Kill Kinetics Of Anti-Tuberculosis
Drugs, And Emergence Of Resistance, In Relation To Metabolic
Activity Of Mycobacterium Tuberculosis. J. Antimicrob.
Chemother. 2010, 65, 2582–2589.
25. Dos Santos Fernandes, G. F.; De Souza, P. C.; Moreno-Viguri, E.;
Santivañez-Veliz, M.; Paucar, R.; Pérez-Silanes, S.; Chegaev, K.;
Guglielmo, S.; Lazzarato, L.; Fruttero, R.; Man Chin, C.; Da Silva,
P. B.; Chorilli, M.; Solcia, M. C.; Ribeiro, C. M.; Silva, C. S. P.;
Marino, L. B.; Bosquesi, P. L.; Hunt, D. M.; De Carvalho, L. P. S.;
De Souza Costa, C. A.; Cho, S. H.; Wang, Y.; Franzblau, S. G.;
Pavan, F. R.; Dos Santos, J. L. Design, Synthesis, And
Characterization Of N-Oxide-Containing Heterocycles With In
Vivo Sterilizing Antitubercular Activity. J. Med. Chem. 2017, 60,
8647–8660.
26. Zhang, B.; Li, J.; Yang, X.; Wu, L.; Zhang, J.; Yang, Y.; Zhao, Y.;
Zhang, L.; Yang, X.; Yang, X.; Cheng, X.; Liu, Z.; Jiang, B.; Jiang, H.;
Guddat, L. W.; Yang, H.; Rao, Z. Crystal Structures of Membrane
Transporter Mmpl3, an Anti-Tb Drug Target. Cell 2019, 176,
636-648.
27. Li, W.; Upadhyay, A.; Fontes, F.L.; North, E.J.; Wang, Y.; Crans,
D.C.; Grzegorzewicz, A.E.; Jones, V.; Franzblau, S.G.; Lee, R.E.;
Crick, D.C.; Jackson, M.; Novel insights into the mechanism of
inhibition of MmpL3, a target of multiple pharmacophores in
Mycobacterium tuberculosis. Antimicrob. Agents Chemother.
2014, 58, 6413-6423.
5. Grange, J.M.; Zumla, A.J. The global emergency of tuberculosis:
what is the cause? J. R. Soc. Promot. Health 2002, 22, 78-81.
6. Eker, B.; Ortmann, J.; Migliori, G. B.; Sotgiu, G.; Muetterlein, R.;
Centis, R.; Hoffmann, H.; Kirsten, D.; Schaberg, T.; Ruesch-
Gerdes, S.; Lange, C. Multidrug- and extensively drug-resistant
tuberculosis, Germany. Emerging Infect. Dis. 2008, 14,
1700−1706.
7. Migliori, G. B.; Loddenkemper, R.; Blasi, F.; Raviglione, M. C. 125
years after Robert Koch’s discovery of the tubercle bacillus: the
new XDR-TB threat. Is ″science″ enough to tackle the
epidemic? Eur. Respir. J. 2007, 29, 423−427.
8. Velayati, A. A.; Farnia, P.; Masjedi, M. R. The totally drug
resistant tuberculosis (TDR-TB). Int. J. Clin. Exp. Med. 2013, 6,
307−309.
9. Caminero, J.A.; Sotgiu, G.; Zumla, A.; Migliori, G.B. Best drug
treatment for multidrug-resistant and extensively drug-
resistant tuberculosis. Lancet Infect. Dis. 2010, 10, 621 – 629.
10. Hartkoorn, R.C.; Chandler, B.; Owen, A.; Ward, S.A.; Bertel
Squire, S.; Back, D.J.; Khoo, S.H. Differential drug susceptibility
of intracellular and extracellular tuberculosis, and the impact
of P-glycoprotein. Tuberculosis 2007, 87, 248-255.
11. Chanwong, S.; Maneekarn, N.; Makonkawkeyoon, L.;
Makonkawkeyoon, S. Intracellular growth and drug
susceptibility of Mycobacterium tuberculosis in macrophages.
Tuberculosis 2007, 87, 130 – 133.
12. Gupta, A.; Kaul, A.; Tsolaki, A.G.; Kishore, U.; Bhakta, S.
Mycobacterium tuberculosis: Immune evasion, dormancy and
resuscitation. Immunobiology 2012, 217, 363-374.
13. Diacon, A.H.; Pym, A.; Grobusch, M.; Patientia, R.; Rustomjee, R.;
Page-Shipp, L.; Pistorius, C.; Krause, R.; Bogoshi, M.;
Churchyard, G.; Venter, A.; Allen, J. The diarylquinoline
TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med.
2009, 360, 2397–405.
14. Pontali, E.; Sotgiu, G.; D'Ambrosio, L.; Centis, R.; Migliori, G.B.
Bedaquiline and multidrug-resistant tuberculosis: a systematic
and critical analysis of the evidence. Eur. Respir. J. 2016, 47,
394-402.
15. Lenaerts, A.J.; Gruppo, V.; Marietta, K.S.; Johnson, C.M.; Driscoll,
D.K.; Tompkins, N.M.; Rose, J.D.; Reynolds, R.C.; Orme, I.M.
Preclinical testing of the nitroimidazopyran PA-824 for activity
against Mycobacterium tuberculosis in a series of in vitro and
in vivo models. Antimicrob. Agents Chemother. 2005, 49, 2294–
301.
16. Tiberi, S.; du Plessis, N.; Walzl, G.; Vjecha, M.J.; Rao, M.; Ntoumi,
F.; Mfinanga, S.; Kapata, N.; Mwaba, P.; McHugh, T.D.; Ippolito,
G.; Migliori, G.B.; Maeurer, M.J.; Zumla, A. Tuberculosis:
progress and advances in development of new drugs,
treatment regimens, and host-directed therapies. Lancet Infect.
Dis. 2018, 18, 183-198.
17. Bhakta, S.; Scalacci, N.; Maitra, A.; Brown, A.K.; Dasugari, S.;
Evangelopoulos, D.; McHugh, T.; Mortazavi, P.N.; Twist, A.;
Petricci, E.; Manetti, F.; Castagnolo, D. Design and synthesis of
1-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-
yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-
yl-N'-((E)-3,7-dimethyl-octa-2,6-dienyl)-ethane-1,2-diamine
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
ACS Paragon Plus Environment